Cincinnati Financial Corporation (CINF) Stock Price Today
Key Stats
- $27.32BMarket Cap
- -Volume
- FinancialsSector
- $192.0352W High
- $149.7452W Low
- -Typical Hold Time
- $26.45BEnterprise Value
- 2.11%Div Yield
- -Trading Activity
Track Cincinnati Financial Corporation (CINF) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Cincinnati Financial Corporation has traded between a low of $149.74 and a high of $192.03, highlighting its annual price range. Buy and sell Cincinnati Financial Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Most Recent News
Bunge Global SA gains insider buy and analyst boost, with price target up 28%
Bunge Global SA saw a director purchase 1,500 shares at $107.60, signaling insider confidence. Analysts have set a mean price target of $138.30, implying a 28.3% upside, driven by strong Q2 performance in soybeans and softseeds that raised earnings o...
Stocks plunge amid inverse ETF drops, legal probes, and earnings worries.
Stocks fell sharply due to various factors including a 58.71% drop in the Defiance Daily Target 2x Short PLTR ETF, driven by strong gains in Palantir Technologies, which the ETF inversely tracks. AdaptHealth shares dropped 38.09% amid a legal investi...
Law firm probes Karyopharm over executive retention bonuses amid stock price drop
Pomerantz LLP is investigating Karyopharm Therapeutics for potential securities fraud related to a retention program granting top executives lump sum cash bonuses between $625,000 and $1,725,000. The announcement led to a 21.45% drop in Karyopharm's ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.